Nephrology News
Biologics Combo Shows Promise As First-Line mRCC Therapy
In a phase 2 trial, atezolizumab plus bevacizumab improved PFS versus sunitinib in patients with renal cell carcinoma expressing PD-L1.
By accepting you will be accessing a service provided by a third-party external to https://galencarepartners.com/